246048-72-6

Basic information

• Product Name: 1,2,5-Oxadiazole-3-carboxylicacid,4-amino-,hydrazide(9CI)
• Synonyms: 1,2,5-Oxadiazole-3-carboxylicacid,4-amino-,hydrazide(9CI);4-Amino-1,2,5-oxadiazol-3-carbohydrazide
• CAS NO: 246048-72-6
• Molecular Formula: C3H5N5O2
• Molecular Weight: 143.11
• Product Categories: AMIDE;AMINEPRIMARY
• Mol File: 246048-72-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.617±0.06 g/cm3(Predicted)
• PKA: 9.78±0.10(Predicted)
• CAS DataBase Reference: 1,2,5-Oxadiazole-3-carboxylicacid,4-amino-,hydrazide(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,5-Oxadiazole-3-carboxylicacid,4-amino-,hydrazide(9CI)(246048-72-6)
• EPA Substance Registry System: 1,2,5-Oxadiazole-3-carboxylicacid,4-amino-,hydrazide(9CI)(246048-72-6)

Safety Data

• Hazardous Substances Data: 246048-72-6(Hazardous Substances Data)

Usage

General Description

1,2,5-Oxadiazole-3-carboxylic acid, 4-amino-, hydrazide (9CI) is a chemical compound that belongs to the class of oxadiazole derivatives. It is a hydrazide derivative of 1,2,5-oxadiazole-3-carboxylic acid and has a molecular formula of C3H5N5O2. 1,2,5-Oxadiazole-3-carboxylicacid,4-amino-,hydrazide(9CI) may have potential applications in the pharmaceutical industry due to its unique chemical structure, and it may be used in the synthesis of various pharmacologically active compounds. Additionally, it may also have uses in the field of organic chemistry for the development of new synthetic methodologies and reactions. As with any chemical compound, proper handling and safety precautions should be taken when working with 1,2,5-oxadiazole-3-carboxylic acid, 4-amino-, hydrazide (9CI).

Upstream product

• 159013-94-2 methyl 3-aminofurazan-4-carboxylate 

Downstream Products

• 167281-96-1 3-amino-4-(1,2,3,4-tetrazol-5-yl)furazan 

Relevant articles and documents

Synthesis and some transformations of 2-[(4-aminofurazan-3-yl)-1H-1,2,4-triazol-5-yl]acetic acid derivatives

Two methods for the synthesis of 1,2,4-triazolylacetic ester bearing an aminofurazanyl substituent at the position 5 were developed. The triazole cycle was formed via the cyclocondensation of 3-aminofurazanecarboxylic acid hydrazide or amidrazone with ethoxycarbonylethyl acetimidate hydrochloride.

Azo1,3,4-oxadiazole as a Novel Building Block to Design High-Performance Energetic Materials

In this study, the azo1,3,4-oxadiazole energetic fragment was first introduced into the energetic materials using a simple synthetic strategy, yielding two symmetrical covalent compounds 4 and 5. All new compounds (3-5) were well-characterized by IR spectroscopy, NMR spectroscopy, thermal analysis, and single-crystal X-ray diffraction analysis. As supported by differenctial scanning calorimetry data, compounds 4 and 5 possess excellent decomposition temperatures as high as 248 and 278 °C, respectively. To the best of our knowledge, 278 °C ranks highest in all 1,3,4-oxadiazole-based energetic compounds. Their energetic performances were evaluated with EXPLO5. Both 4 and 5 show good detonation velocities (D) of 8409 and 8800 m s-1 and detonation pressures (P) of 29.3 and 35.1 GPa, comparable to RDX (D: 8795 m s-1, P: 34.9 GPa). Furthermore, on the basis of the single-crystal data, quantum-chemical calculations were employed to better understand their intrinsic structure-property relationship. All these positive results indicate the superior potential of the azo1,3,4-oxadiazole backbone for designing next generation of energetic materials.

Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety

Acyl hydrazone is an important functional group for the discovery of bioactive small molecules. This functional group is also recognized as a pan assay interference structure. In this study, a new small-molecule inhibitor for the β-catenin/Tcf protein-protein interaction (PPI), ZINC02092166, was identified through AlphaScreen and FP assays. This compound contains an acyl hydrazone group and exhibits higher inhibitory activities in cell-based assays than biochemical assays. Inhibitor optimization resulted in chemically stable derivatives that disrupt the β-catenin/Tcf PPI. The binding mode of new inhibitors was characterized by site-directed mutagenesis and structure-activity relationship studies. This series of inhibitors with a new scaffold exhibits dual selectivity for β-catenin/Tcf over β-catenin/cadherin and β-catenin/APC PPIs. One derivative of this series suppresses canonical Wnt signaling, downregulates the expression of Wnt target genes, and inhibits the growth of cancer cells. This compound represents a solid starting point for the development of potent and selective β-catenin/Tcf inhibitors (Chemical Equation).